In the present study, we investigated the effects of empagliflozin and dapagliflozin, the two SGLT2 inhibitors included in the HF guidelines, on oxidative stress and MAO expression in human atrial samples harvested from overweight non-diabetic patients with HF with all spectrums of ejection fraction. This evidence concerns the gene SLC5A2 and hydrops fetalis.